Boehringer Ingelheim explore overcoming challenges to industry in the device development process at Asthma & COPD 2017

SMi will return to London once more for the 13th annual Asthma & COPD show taking place on the 29th & 30th March 2017. End Quote

(1888PressRelease) February 14, 2017 - The 2017 agenda will bring together senior scientists and respiratory and inhalation specialists to discuss ongoing challenges and explore leading strategies to novel treatments and solutions for these respiratory diseases.

Stefan Leiner, Chemical-Pharmaceutical Expert from Boehringer Ingelheim will be speaking at this year's event on 'Overcoming challenges to industry in the device development process'. Stefan will discuss: moving away from generic development, taking age group into consideration when developing a device; considerations for paediatric and elderly patients, incorporating clinical trials as a key step in obtaining device approval as well as USP regulatory updates on spacers in new devices.

In the lead up to the event, SMi conducted a quick Q & A with Stefan to discuss the current landscape of the fields of asthma & COPD.

"SMi: What do you see as the greatest hurdle to asthma and COPD treatments?
Stefan: One hurdle is the complexity of inhalers: Inhalation therapy requires attentive patients. The second hurdle is the long-term treatment which triggers adherence problems. And thirdly, current therapies are not curing, todays therapies target symptoms, not the cause of the diseases.

SMi: What should be done to address this?
Stefan: We made some progress to make inhalers easier. However, a lot of research is needed to move to curing - we need new approaches."

Inhalers will be just one of the topics discussed throughout the two days. Other talking points include: regulatory updates, formulation development, therapeutic developments, personalised treatments, biologics, biomarkers, COPD updates, The Salford Lung Study and so much more from respiratory experts from MHRA, GSK, Boehringer Ingelheim, Glenmark Pharmaceuticals, Janssen, Teva, AstraZeneca, MedImmune, Mylan, Imperial College of London, Actavis and many more...

A CPD certified pre-conference workshop will be hosted alongside the conference by Cambridge Consultants on 'The future of Asthma & COPD management; from connected inhalers to therapy management'.

For further information on the two day agenda or those wishing to attend, visit the event website on www.asthma-copd.co.uk/1888

For sponsorship packages: Contact Alia Malick on +44 (0)20 7827 6168 or email amalick ( @ ) smi-online dot co dot uk

For group delegate bookings: Contact Ameenah Begum on +44 (0)20 7827 6166 or email
abegum ( @ ) smi-online dot co dot uk

For media enquiries, contact Zoe Gale on +44 20 7827 6138 or zgale ( @ ) smi-online dot co dot uk

13th annual Asthma & COPD
29-30 March 2017
London, UK
www.asthma-copd.co.uk/1888
Sponsored by Vitalograph and Nemera
Contact e-mail: zgale ( @ ) smi-online dot co dot uk
Contact tel: +44 (0) 207 827 6166
#asthmacopdsmi

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

###

space

Other Related Press Releases